WO2001035932A3 - Sustained drug delivery from structural matrices - Google Patents

Sustained drug delivery from structural matrices Download PDF

Info

Publication number
WO2001035932A3
WO2001035932A3 PCT/US2000/031754 US0031754W WO0135932A3 WO 2001035932 A3 WO2001035932 A3 WO 2001035932A3 US 0031754 W US0031754 W US 0031754W WO 0135932 A3 WO0135932 A3 WO 0135932A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
control over
drug delivery
matrices
vivo
Prior art date
Application number
PCT/US2000/031754
Other languages
French (fr)
Other versions
WO2001035932A2 (en
Inventor
David J Mooney
Lonnie D Shea
Martin C Peters
Elly Liao
Thomas P Richardson
Original Assignee
Univ Michigan
David J Mooney
Lonnie D Shea
Martin C Peters
Elly Liao
Thomas P Richardson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, David J Mooney, Lonnie D Shea, Martin C Peters, Elly Liao, Thomas P Richardson filed Critical Univ Michigan
Priority to AU16228/01A priority Critical patent/AU1622801A/en
Publication of WO2001035932A2 publication Critical patent/WO2001035932A2/en
Publication of WO2001035932A3 publication Critical patent/WO2001035932A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are pre-fabrication methods for preparing particular 3-dimensional structural matrices containing proteins and/or drugs, the resultant compositions and in vitro and in vivo methods for the prolonged release of proteins and/or drugs in various biological environments. The pre-fabrication processes provide protein- and/or drug-matrix materials with both high incorporation efficiencies and control over sustained protein and/or drug release. The resultant matrices are thus particularly useful in vivo biodelivery embodiments, providing control over spatial delivery and differential release kinetics of multiple biological components.
PCT/US2000/031754 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices WO2001035932A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16228/01A AU1622801A (en) 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16619199P 1999-11-18 1999-11-18
US60/166,191 1999-11-18

Publications (2)

Publication Number Publication Date
WO2001035932A2 WO2001035932A2 (en) 2001-05-25
WO2001035932A3 true WO2001035932A3 (en) 2002-03-07

Family

ID=22602185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031754 WO2001035932A2 (en) 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices

Country Status (2)

Country Link
AU (1) AU1622801A (en)
WO (1) WO2001035932A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
AUPR289601A0 (en) * 2001-02-05 2001-03-01 Commonwealth Scientific And Industrial Research Organisation Method of tissue repair
AU2002227792B2 (en) * 2001-02-05 2007-12-13 Industrial Technology Research Institute Methods and devices for tissue repair
GB0115320D0 (en) 2001-06-22 2001-08-15 Univ Nottingham Matrix
WO2004108810A1 (en) * 2003-06-06 2004-12-16 Humanautocell Gmbh Matrix, cell implantation and method for their production and use
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2008526749A (en) * 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド Sustained release delivery of PDGF using self-assembling peptide nanofibers
DK2347775T3 (en) 2005-12-13 2020-07-13 Harvard College TEMPLATES FOR CELL TRANSPLANTATION
CA2641860C (en) 2006-02-09 2015-07-14 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
ES2664229T3 (en) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Compositions and methods of biomatrix-PDGF for the treatment of rotator cuff injuries
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
ES2358703B1 (en) * 2007-11-14 2012-03-21 Universidad Del Pais Vasco EMPLOYMENT OF MICROPART�? CULAS FOR USE AS VACCINES AND THE RELEASE OF BIOLOGICALLY ACTIVE MOLECULES.
CN102006891B (en) 2008-02-13 2017-04-26 哈佛学院董事会 Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
US8492335B2 (en) 2010-02-22 2013-07-23 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
EP2585053A4 (en) * 2010-06-25 2014-02-26 Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
EP2624873B1 (en) 2010-10-06 2019-12-04 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
EP3417876B1 (en) 2011-04-28 2021-03-31 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
LT2838515T (en) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
CN107073090A (en) 2014-04-30 2017-08-18 哈佛学院董事会 With reference to vaccine device and kill cancer cell method
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN109072197A (en) 2016-02-06 2018-12-21 哈佛学院校长同事会 It is immune to rebuild to remold hematopoiesis nest
CN109789092A (en) 2016-07-13 2019-05-21 哈佛学院院长等 Antigen presenting cell simulates bracket and its preparation and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044027A1 (en) * 1997-03-31 1998-10-08 The Regents Of The University Of Michigan Open pore biodegradable matrices
WO1999058656A2 (en) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Sustained dna delivery from structural matrices
WO2000056375A2 (en) * 1999-03-19 2000-09-28 The Regents Of The University Of Michigan Mineralization and cellular patterning on biomaterial surfaces

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044027A1 (en) * 1997-03-31 1998-10-08 The Regents Of The University Of Michigan Open pore biodegradable matrices
WO1999058656A2 (en) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Sustained dna delivery from structural matrices
WO2000056375A2 (en) * 1999-03-19 2000-09-28 The Regents Of The University Of Michigan Mineralization and cellular patterning on biomaterial surfaces

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOPFERICH A: "Bioerodible implants with programmable drug release", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 44, no. 2, 17 February 1997 (1997-02-17), pages 271 - 281, XP004015255, ISSN: 0168-3659 *
SHEA L D: "DNA delivery from polymer matrices for tissue engineering", NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 17, no. 6, June 1999 (1999-06-01), pages 551 - 554, XP002121278, ISSN: 1087-0156 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8870954B2 (en) 2008-09-09 2014-10-28 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries

Also Published As

Publication number Publication date
AU1622801A (en) 2001-05-30
WO2001035932A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001035932A3 (en) Sustained drug delivery from structural matrices
IL153011A0 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2338358A1 (en) Compounds and compositions for delivering active agents
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
NO962088L (en) Preparation for in vivo production of therapeutic products
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
EP0993831A3 (en) Compounds and compositions for delivering active agents
CA2233108A1 (en) Complex of y-cyclodextrin and retinol or retinol derivatives, processes for their preparation and their use
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
AU2845599A (en) Pharmaceutical compositions and their use
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
WO2003028696A3 (en) Compositions for delivery of drug combinations
EP2213302A3 (en) DR4 antibodies and uses thereof
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2287534A1 (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
EP1143999A3 (en) Lipoprotein complexes and compositions containing them
AU5812800A (en) Pharmaceutical preparation
HUP0003207A2 (en) Proliposome powders for inhalation stabilised by tocopherol, pharmaceutical compositions containing the same and the use of them
WO2002059147A3 (en) Activatable cytolytic or drug delivery peptides and uses thereof
CA2305359A1 (en) Drug delivery system
AU1594897A (en) Solid instant-release forms of administration and process for producing the same
AU1258000A (en) Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)